PROTHENA PLC (PRTA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PRTA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRTA | Director | 63 | ["Scientific expertise in biopharmaceutical research and/or in relevant medical fields", "Experience in the design and implementation of clinical studies in support of drug development", "Experience with regulation in the healthcare industry", "Experience overseeing and driving strategic direction and growth of an organization", "Experience or expertise in financial accounting and reporting processes or the financial management of an organization", "Experience with legal and ethical and public policy issues in the healthcare industry", "Service on a public company board other than Prothena\u2019s", "Experience in capital market transactions or mergers and acquisitions", "Experience in attracting and retaining top talent and building organizational culture"] | ["Compensation Committee", "Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALKS | Independent Director; Chair | 63 | ["Served as President of Alkermes Pharma Ireland Limited","Chief Financial Officer of Elan Corporation","Chief Executive of Pembroke Capital Limited","Experience in managing corporate entities in Ireland","Chartered accountant","audit committee financial expert"] | ["Audit and Risk (C)","Financial Operating","Nominating and Corporate Governance","Audit and Risk (Chair)","Audit and Risk Committee","Financial Operating Committee","Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Shane M. Cooke is the former President of Alkermes plc (a biopharmaceutical company), a position he held from 2011 to 2018. Prior to that, he served as Head of Elan Drug Technologies and Executive Vice President of Elan Corporation, plc (from 2007 to 2011), where he also served as Chief Financial Officer (from 2001 to 2011) and as a director (from 2005 to 2011). Mr. Cooke has also held a number of senior positions in finance in the banking and aviation industries. He is a director of Alkermes plc (a biopharmaceutical company whose board he joined in 2018), and served as a director of Endo International plc (a biopharmaceutical company) (from 2014 to April 2024), and as a director (from 2019 to 2020) and chair of the board (from 2020 until its acquisition by Clayton, Dubilier & Rice, LLC in 2021) of UDG Healthcare plc (a pharmaceutical services company). Mr. Cooke earned his Bachelor of Commerce and Master of Accounting degrees from University College Dublin, Ireland, and is a chartered accountant. He has served on our Board since 2012. Age: 63 The Board concluded that Mr. Cooke should continue to serve as a director given his significant operational, financial, commercial, and management experience in the biotechnology industry, as well as his qualification as a chartered accountant. The Board also considered his Irish residency and experience as a director and an executive officer of other Irish companies traded on U.S. stock exchanges.